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Abstract
Background: Accurate evaluation of axillary lymph node (ALN) involvement is mandatory before
treatment of primary breast cancer. The aim of this study is to compare preoperative diagnostic
accuracy between positron emission tomography/computed tomography with 18F-
fluorodeoxyglucose (18F-FDG PET/CT) and axillary ultrasonography (AUS) for detecting ALN
metastasis in patients having operable breast cancer, and to assess the clinical management of
axillary 18F-FDG PET/CT for therapeutic indication of sentinel node biopsy (SNB) and preoperative
systemic chemotherapy (PSC).
Methods: One hundred eighty-three patients with primary operable breast cancer were recruited.
All patients underwent 18F-FDG PET/CT and AUS followed by SNB and/or ALN dissection
(ALND). Using 18F-FDG PET/CT, we studied both a visual assessment of 18F-FDG uptake and
standardized uptake value (SUV) for axillary staging.
Results: In a visual assessment of 18F-FDG PET/CT, the diagnostic accuracy of ALN metastasis was
83% with 58% in sensitivity and 95% in specificity, and when cut-off point of SUV was set at 1.8,
sensitivity, specificity, and accuracy were 36, 100, and 79%, respectively. On the other hand, the
diagnostic accuracy of AUS was 85% with 54% in sensitivity and 99% in specificity. By the
combination of 18F-FDG PET/CT and AUS to the axilla, the sensitivity, specificity, and accuracy
were 64, 94, and 85%, respectively. If either 18F-FDG PET uptake or AUS was positive in allixa, the
probability of axillary metastasis was high; 50% (6 of 12) in 18F-FDG PET uptake only, 80% (4 of 5)
in AUS positive only, and 100% (28 of 28) in dual positive. By the combination of AUS and 18F-FDG
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PET/CT, candidates of SNB were more appropriately selected. The axillary 18F-FDG uptake was
correlated with the maximum size and nuclear grade of metastatic foci (p = 0.006 and p = 0.03).
Conclusion: The diagnostic accuracy of 18F-FDG PET/CT was shown to be nearly equal to
ultrasound, and considering their limited sensitivities, the high radiation exposure by 18F-FDG PET/
CT and also costs of the examination, it is likely that AUS will be more cost-effective in detecting
massive axillary tumor burden. However, when we cannot judge the axillary staging using AUS
alone, metabolic approach of 18F-FDG PET/CT for axillary staging would enable us a much more
confident diagnosis.
Background
Axillary lymph node (ALN) status is an important predic-
tor regarding recurrence and survival of patients having
primary breast cancer. Recently, sentinel node biopsy
(SNB) has been introduced as a minimally invasive proce-
dure to evaluate ALN status [1].
Accurate evaluation of ALN involvement is mandatory
before treatment of primary breast cancer by following
reasons; (1) ALN status is related to staging of disease and
patients prognosis. (2) SNB can be beneficial for the
patients to whom the presence of ALN involvement is not
preoperatively detectable. They can avoid ALN dissection
(ALND) when metastatic foci in sentinel nodes (SNs) are
absent. (3) The status of ALN might influence on the deci-
sion of primary systemic chemotherapy (PSC). Patients
with involved ALNs can be a candidate for PSC.
In our institute, we have carried out the identification of
SNs using tin-colloid radioisotope technique [2]. SNs can-
not be detected in patients having a massive ALN involve-
ment because of poor uptake of radiotracer in SNs mostly
replaced by tumor. Therefore, clinically node-positive
patients are not candidates for SNB. Axillary ultrasonogra-
phy (AUS) has been the most easy-applicable imaging
tool for clinical staging of ALN status in patients having
primary breast cancer [3,4].
We have used AUS to identify breast cancer patients who
were eligible for optimal SNB [5]. Although AUS is not
complete for the accurate determination of axillary nodal
status, this tool is particularly sensitive for selecting
patients with massive tumor burden. Actually, in a series
of patients who were judged as candidates for SNB by AUS
only, we reported that diagnostic accuracy of ALN status
could be achieved 98.6%[5]. Positron emission tomogra-
phy with 18F-fluorodeoxyglucose (18F-FDG PET) is
expected to be a non-invasive approach to evaluate
patients having ALN involvement. Recent studies using
18F-FDG PET alone have shown low sensitivity, acceptable
specificity, and acceptable positive predictive values in
detection of ALN involvement [6-9]. In a prospective mul-
ticenter study in the U.S.A, diagnostic performance of 18F-
FDG PET in axillary staging showed relatively low sensitiv-
ity (mean 61%, ranging from 54% to 67%), and high spe-
cificity (mean 80%, ranging from 79 to 81%), when
abnormal axillary focus was considered positive. In the
same study, the 18F-FDG PET in axillary staging had a
lower sensitivity of 32% and a higher positive predictive
value of 90%, when the cut-off of standerd uptake value
(SUV) 1.8 or greater [10]. Veronesi et al also reported that
the sensitivity of 18F-FDG PET for detecting ALN involve-
ment was 37%, but specificity and positive predictive
value were 96% and 88%, respectively, at the threshold of
SUV 1.2 [11].
Recently, fusion imaging systems combining 18F-FDG PET
and computed tomography (18F-FDG PET/CT) have come
to be applied in breast oncology. 18F-FDG PET/CT can vis-
ualize anatomical location of the hypermetabolic cancer
lesions better than 18F-FDG PET or CT alone [12,13].
Therefore, the application of 18F-FDG PET/CT might be
very informative for detecting both regional lymph node
involvement and distant metastasis.
We studied both a visual assessment of 18F-FDG uptake
and SUV for axillary staging, and compared the diagnostic
accuracy between preoperative 18F-FDG PET/CT and pre-
operative ultrasound in detecting ALN metastasis. We dis-
cussed the clinical management of the combonation of
axillary  18F-FDG PET/CT and AUS for the selection of
proper candidates of SNB and PSC.
Methods
Patients
The study was done in accordance with the ethical princi-
ples of the Declaration of Helsinki and was approved by
the institutional review board in the National Defense
Medical College (NDMC). Informed consents were
obtained from all patients with regard to 18F-FDG PET/CT
examination and the entry into the present study.
This prospective study enrolled a series of 183 patients
having primary breast cancer proven by core needle
biopsy at the National Defense Medical College Hospital
from April 2005 through August 2007. For axillary stag-
ing, all patients underwent both 18F-FDG PET/CT and
ultrasonography within 5 weeks before surgery. PatientsBMC Cancer 2008, 8:165 http://www.biomedcentral.com/1471-2407/8/165
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with diabetes mellitus or pregnancy, those who under-
went primary systemic therapy, those who underwent
excisional biopsy were excluded. During the entry period,
we experienced 15 patients who were diagnosed by 18F-
FDG PET/CT to have breast cancer with distant metas-
tases, comprising four distant lymph node metastases,
nine bone metastases, and two lung metastases. Patients
having distant metastases were also ineligible for this
study.
Axillary ultrasound examination
AUS was performed using ProsoundII SSD 6500 (Aloka,
Tokyo, Japan) employing a 10-MHz linear array trans-
ducer. AUS criteria in our institute were described previ-
ously [5]. In brief, homogeneously hypoechoic lymph
nodes with diameters of 10 mm or more and in oval or
round shape were defined as AUS-positive and were con-
sidered to be potentially extensive nodal involvement.
Lymph nodes with central hyperechoic area and/or with
diameter of less than 10 mm, defined as AUS-negative
were considered to be clinically node-negative. One expe-
rienced ultrasonographer (T.K) performed axillary exami-
nation of operable patients. At least two breast surgeons
discussed and determined AUS status together with the
ultrasonographer in weekly conference.
Surgery and Sentinel node biopsy procedure
The 183 patients underwent mastectomy or breast-con-
serving surgery with SNB and/or ALND. SNB was per-
formed using the procedure described previously [2].
According to SNB protocol in our institute, patients hav-
ing AUS negativity were eligible for SNB and were option-
ally performed SNB after the acquisition of informed
consent. For patients having AUS positivity or those who
rejected SNB, ALND was performed.
SNs were intraoperatively examined histopathologically.
Biopsied SNs were cut into 2-mm-thick slices, and his-
topathological sections were made from each slice. These
sections were stained with hematoxylin and eosin, and at
least two pathologists examined the sections. All patients
having SN metastasis recieved ALND. If SNs were free of
cancer cells, ALND was omitted.
18F-FDG PET/CT and quantification of 18F-FDG uptake in 
axilla
All patients received 18F-FDG PET/CT scans (Biograph
LSO Emotion, 3D model, Siemens, Germany) at Tokoro-
zawa PET Diagnostic Imaging Clinic (Tokorozawa,
Japan). Blood glucose level was measured in each patient
and did not exceed 120 mg/dl.
Patients fasted at least 4 hours before 18F-FDG PET study.
One hour after intravenous administration of 3.7 Mbq/kg
18F-FDG, a transmission scan using CT (SOMATO Emo-
tion, 16-slice configuration, pitch 1.83, Siemens, Ger-
many) for attenuation correction and anatomical imaging
was acquired for 90 sec. IV contrast was not administered
to patients for the CT portion of the 18F-FDG PET/CT.
Back projection image was obtained after Gaussian filter
was applied. The spatial resolution of the reconstructed
images was 6.0–7.0 mm in cranio-caudal, 6.3–7.1 mm in
right-left and 6.3–7.1 mm in anterior-posterior directions.
A regions of interest (ROI) was placed in the axillary
lesion, including the highest uptake area (circle ROI, 2 cm
in diameter), and SUV maximum in the ROI was calcu-
lated. The SUV was decay-corrected tissue activity divided
by the injected dose per patient body, and was calculated
using the following formula: SUV = activity in region of
interest/decay factor of F-18 (MBq/ml)/injected dose
(MBq/kg body weight).
CT images were also available for evaluation. Visual
assessment of 18F-FDG uptake was carried out by at least
two experienced nuclear medicine radiologists, and
abnormal axillary uptake greater than background activity
was interpreted as suspicious nodal involvement. Semi-
quantitative measurement of SUV was done on any axil-
lary focus with abnormal uptake.
Determination of the optimal SUV cut-off points
To determine the optimal SUV cut-off point, the tentative
SUV cut-off point was established, ranging from 0.8 to 3.0
with 0.2 to 0.3 increments. SUV of the cut-off point or
greater was defined as positive and SUV less than the
point was defined as negative. The SUV of 0.4 is the lowest
limit of visible uptake of 18F-FDG. Based on each SUV cut-
off point, the diagnostic accuracy of 18F-FDG PET/CT
(positive or negative) was evaluated by means of sensitiv-
ity, specificity, positive predictive value (PPV), and nega-
tive predictive value (NPV).
Histopathological study
The number, the maximum size, and nuclear grade of
involved ALNs were histopathologically examined.
Statistical analysis
Statistical analysis was performed using Statview 5.0 ver-
sion (SAS Institute Inc). As univariate analysis, Mann-
Whitney U test and chi square test were used to establish
the correlation between clinicopathological variables and
axillary SUV. P value of 0.05 or less was defined as statis-
tical significance.
Results
Patient characteristics
Patient age, pathological T factor, histological type,
nuclear grade, hormonal receptor status and c-erbB2 sta-BMC Cancer 2008, 8:165 http://www.biomedcentral.com/1471-2407/8/165
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tus of the primary tumors, and SUV of the primary tumors
and axillary uptake are listed in Table 1, ALN involvement
was histopathologically detected in 59 (32%) of 183
patients.
The mean SUV of the primary tumor in the 183 patients
was 4.3, ranging from 0.9 to 17.8, and the mean SUV of
the axilla was 3, ranging 0.4 to 11.3. The SUVs of 0.4 and
11.3 were the lowest point and the highest point to visu-
alize  18F-FDG uptake, respectively. The mean interval
between 18F-FDG PET/CT and surgery was 29 days. One
hundred twenty-five (68%) of the 183 patients underwent
initial SNB. One hundred twenty-four (99%) of the 125
patients were successfully performed SNB. The number of
removed SNs per patient was 2.4 on an average. Metas-
tases to SNs were positive in 24 (19%) patients, and all of
these patients underwent ALND. Metastases to the SNs
were negative in 100 (81%) patients, and none of them
recieved further axillary surgery. Other 58 (32%) patients
underwent ALND without SNB.
Diagnostic performance of 18F-FDG PET/CT and 
ultrasonography in axillary staging
Diagnostic performance for detecting axillary involve-
ment was compared between 18F-FDG PET/CT and ultra-
sonography (Table 2).
By visual assessment of 18F-FDG PET/CT, axillary uptake
was positive in 40 (22%) patients and negative in 143
(78%) patients. Of these 40 axillary-positive patients, 34
(85%) were truely positive, whereas 6 (15%) were false
positive. Of the 143 axillary- negative patients, 118 (83%)
patients were truely negative, whereas 25 (17%) patients
were false negative. Sensitivity, specificity, PPV, NPV, and
accuracy of visual assessment of 18F-FDG PET/CT were 58,
95, 85, 83, and 83%, respectively.
Table 1: Patient characteristics
Variables Number 183 % 100
Age mean [range] 57 [32–81]
<45 33 18
45 &#x2266; 150 82
pT-stage pTis 10 5
pT1 91 50
pT2 68 37
pT3 14 8
Histology DCIS 9 5
IDC 158 86
ILC 9 5
Apocrine 2 1
Mucinous 2 1
Squamoid 1 1
Paget 2 1
Nuclear grade 1 59 32
25 1 2 8
36 9 3 8
Not graded 4 2
Nodal metastasis negative 124 68
positive 59 32
Estrogen receptor (ER) 10%> 44 24
10% &#x2266; 139 76
Progesterone receptor(PgR) 10%> 63 34
10% &#x2266; 120 66
c-erbB-2 (HER2) 0 to 2+ 152 83
3+/FISH Amp 28 15
unknown 3 2
Primary axillary approach Ax dissection 58 32
SNB 125 68
SUV of the primary tumor mean [range] 4.3 [0.9–17.8]
SUV of axillary uptake* mean [range] 3.0 [0.4–11.3]
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Mucinous, mucinous carcinoma; Apocrine, apocrine. 
carcinoma; Squamoind, Squamoid carcinoma; Paget, Paget's disease; FISH Amp, FISH Amplication; Ax, axillary; SNB, sentinel node biopsy; SUV, 
Standardized Uptake Value; *Visible uptake of 18F-FDGBMC Cancer 2008, 8:165 http://www.biomedcentral.com/1471-2407/8/165
Page 5 of 10
(page number not for citation purposes)
The accuracy of diagnosis of 18F-FDG PET/CT was com-
pared among various SUV cut-off points ranging from 0.8
to 3.0, using entire data set of 183 patients.
When a SUV cut-off points were set from 0.8 up to 1.8,
specificity increased from 95% to 100%, but sensitivity
decreased from 51% to 36%. As SUV increased over 1.8,
specificity of 100% did not vary, but sensitivity further
decreased. When the SUV was 1.8, PPV, NPV and accuracy
were 100%, 77%, and 79%, respectively. Therefore, the
SUV of 1.8 achieved excellent specificity and PPV, but low
sensitivity in comparison with visual assessment.
Ultrasonography detected 33 (18%) AUS-positive
patients and 150 (82%) AUS-negative patients. Of the 33
AUS-positive patients, thirty-two patients (97%) were
truely positive, and one patient (3%) was false-positive.
Of the 150 AUS-negative patients, 123 (82%) were truely
negative, whereas 27 (18%) were false-negative. Sensitiv-
ity, specificity, PPV, NPV, and accuracy were 54, 99, 97,
82, and 85%, respectively.
Combined with visual assessment of 18F-FDG uptake and
AUS, 138 (75%) patients with double-negative 18F-FDG
uptake and AUS were considered to be nodal negative,
and 45 (25%) patients with positive finding in the visual
assessment of 18F-FDG uptake and/or AUS were consid-
ered to be nodal positive. Sensitivity, specificity, PPV,
NPV, and accuracy of the combination were 64, 94, 84,
85, and 85%, respectively.
Feasibility of SNB for patients having negative AUS
Of the 150 patients having negative AUS, 125 (83%) con-
sented and underwent SNB. Table 3 shows diagnostic per-
formance of SNB in axillary staging in AUS-negative
patients. SNB identification rate was 99.2% (124 of 125
patients). Twenty five patients (20%) had axillary nodal
metastasis in permanent pathology. Intraoperative patho-
logical diagnosis of metastasis in SNB was accurately per-
formed in 123 (99%) of 124 patients. One patient (1%)
was false negative by frozen section intraoperatively, but a
micrometastatic deposit was postoperatively detected in
one of sentinel nodes by permanent histology. With
regard to intraoperative pathological diagnosis of metas-
tasis in SNB, sensitivity, specificity, PPV, NPV and overall
accuracy were 96, 100, 100, 99, and 99% respectively in
Table 3A.
In the 12 AUS-negative but 18F-FDG uptake positive
patients who consented and recieved SNB, 6 (50%) had
ALN involvement. One (8%) patient was false negative.
With regard to intraoperative pathological diagnosis of
SLN, sensitivity, specificity, PPV, NPV, and overall accu-
racy were 83, 100, 100, 86, and 92%, respectively in Table
3B.
In the 112 AUS-negative and 18F-FDG uptake negative
patients, who consented and underwent SNB, 19 (17%)
had ALN involvement. With regard to intraoperative path-
ological diagnosis of SNB, sensitivity, specificity, PPV,
NPV, and overall accuracy were all 100% in Table 3C.
Axillary nodal clinicopathological factors correlated with 
18F-FDG uptake
Table 4 shows correlation of axillary 18F-FDG uptake with
nodal clinicopathological factors of 59 patients having
ALN involvement. The maximum size and nuclear grade
of involved ALN were significantly correlated with 18F-
FDG uptake at SUV cut-off point 1.8 (p = 0.006 and 0.03,
respectively). The number of involved ALNs was not cor-
Table 2: Diagnostic performance of 18 F-FDG PET/CT and ultrasonography in axillary staging
18F-FDG uptake TP TN FP FN Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
Visual assessment 34 118 6 25 57.6 95.2 85 82.5 83.1
SUV cutoff point
0.8 30 118 6 29 50.8 95.2 83.3 80.3 80.9
1.3 24 122 2 35 40.7 98.4 92.3 77.7 79.8
1.5 21 123 1 38 35.6 99.2 95.5 76.4 78.7
1.8 21 124 0 38 35.6 100 100 76.5 79.2
2 20 124 0 39 33.9 100 100 76.1 78.7
3 16 124 0 43 27.1 100 100 74.3 76.5
AUS 32 123 1 27 54.2 99.2 97 82 84.7
Visual assessment of 18F-FDG uptake Combined with 
AUS
38 117 7 21 64.4 94.4 84.4 84.8 84.7
AUS, Axillary ultrasonography; TP, True positive; TN, True negative; FP, False positive; FN, False negative; PPV, Positive predictive value; NPV, 
Negative Predictive value;BMC Cancer 2008, 8:165 http://www.biomedcentral.com/1471-2407/8/165
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related with 18F-FDG uptake at SUV cut-off point 1.8 (p =
0.15).
Categories of 18F-FDG PET/CT combined with ultrasound 
for indications of ALND and PSC
Table 5 indicates four categories which were divided by
clinical findings of 18F-FDG PET/CT and AUS to the axilla.
We used a visual assessment of 18F-FDG uptake which
proved to be a reproducible method and have acceptable
sensitivity and specificity [6]. Of all 183 patients, 138
(75%) patients who had negative AUS with negative axil-
lary  18F-FDG uptake were classified as category 1. Fre-
quency of ALNs involvement was only 21 (15%), 12
(57%) of these 21 patients had single involved ALNs. The
maximum size of involved ALNs was 10 mm or smaller in
17 (81%) of 21 patients. The nuclear grade of involved
ALNs was grade 1 or 2 in 16 (76%), and grade 3 in only 5
(24%).
Twenteen (7%) patients who had negative AUS but posi-
tive axillary 18F-FDG uptake were classified as category 2.
In category 2, ALNs involvement was detected in 6 (50%)
Table 3: Diagnostic performance of SNB for axillary staging in AUS-negative patients
No. of patients
Permanent histopathology
Intraoperative frozen Histopathology Total Metastasis positive Metastasis negative
A. Total (n = 124)
Metastasis positive 24 24 0
Metastasis negative 100 1 99
Total 124 25 99
B. 18F-FDG uptake positive (n = 12)
Metastasis positive 5 5 0
Metastasis negative 7 1 6
Total 12 6 6
C. 18F-FDG uptake negative (n = 112)
Metastasis positive 19 19 0
Metastasis negative 93 0 93
Total 112 19 93
Note; SNB, sentinel node biopsy; AUS, axillary ultrasound; No., Number; SNB identification rate 99.2% (124 of 125 cases)
Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPN), and accuracy overall were 96, 100, 100, 99, and 99%, 
respectively in A. Sensitivity, specificity, PPV, NPV, and overall accuracy were 83, 100, 100, 86, and 92%, respectively in B.
Sensitivity, specificity, PPV, NPV, and overall accuracy were 100, 100, 100, 100, and 100%, respectively in C.
Table 4: Axillary nodal clinicopathological factors correlated with 18 F-FDG uptake
Clinicopathological factors SUV cut-off 1.8 No. of pts Average SD p-value
No. of involved ALNs Low 38 3.6 5 0.15
High 21 6.9 7
The maximum size (mm) Low 38 8.6 6.4 0.006
High 21 14.6 7.9
SUV No. of pts Grade No. ofpts p-value
Nuclear grade Low 38 Grade1/2 27 0.03
Grade3 11
High 21 Grade1/2 9
Grade3 12
SUV, Standardized uptake value; No, Number; pts, patients; SD, Standard derivationBMC Cancer 2008, 8:165 http://www.biomedcentral.com/1471-2407/8/165
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of 12. A single ALN involvement was present in 5 (83%)
of these 6. All 6 patients had ALNs involvement with the
maximum size of less than 10 mm in category 2. Nuclear
grade was 1 or 2 in 3 (50%) patients, whereas nuclear
grade was 3 in 2 (50%).
Five (3%) patients who had positive AUS but negative
axillary  18F-FDG uptake were classified as category 3.
Twenty-eight (15%) patients who had double-positive
nodal status of AUS and 18F-FDG uptake were classified as
category 4. Four (80%) of 5 patients in category 3 had
ALNs involvement and all patients in category 4 had ALNs
involvement. Especially 2-or-more involved ALNs were 2
(50%) of 4 cases in category 3, and 19 (68%) of 28 cases
in category 4. The maximum size of involved ALNs was 10
mm or more in 2 (50%) of 4 cases in category 3 and in 22
(79%) of 24 cases in category 4.
Nuclear grade was 1 or 2 in all 4 (100%) cases in category
3, whereas nuclear grade was 1 or 2 in 13 (46%) of 28
cases in category 4.
Diagnostic performance of SNB in 18F-FDG-positive and 
AUS-negative patients
Table 6 shows diagnostic performance of SNB for axillary
staging in 18F-FDG-positive and AUS-negative patients of
category 2. Six (50%) of 12 patients had involved SNs and
others (50%) had no involved SNs in spite of 18F-FDG
uptake. No metastases were found in non-SNs in all
patients that had involved SNs and received aubsequent
axillary dissection.
Discussion
Visual assessment of 18F-FDG PET/CT for the axillary 
staging
In visual assessment of 18F-FDG PET/CT to the axilla, we
demonstrated that diagnostic accuracy of 18F-FDG PET/CT
was almost equivalent to that of AUS for detecting of ALN
involvement in patients with primary breast cancer. Visual
assessment of 18F-FDG uptake to the axilla achieved
higher sensitivity than AUS, and the specificity and PPV of
18F-FDG PET/CT were acceptably high, 95%, and 85%,
respectively.
There were 40 (22%) of 183 patients having axillary
uptake of 18F-FDG. Six (15%) of these patients had no
metastasis of ALNs. The reason of these false positive for
the 18F-FDG uptake is not known, but reactive lymphade-
nopathy caused by breast biopsy would lead to false pos-
itive results [9,14].
AUS showed limited sensitivity equal to 18F-FDG PET/CT
for detecting ALN involvement, and showed almost per-
fect specificity and PPV. According to diagnostic perform-
Table 5: Categories of 18 F-FDG PET/CT combined with ultrasonography for indications of ALND/PSC
Category 1 2 3 4
AUS - - + +
18F-FDG-uptake - + - +
No. of involved ALNs
0 117 (85) 6 (50) 1 (20) 0 (0)
1 12 (9) 5 (42) 2 (40) 9 (32)
2 &#x2266; Involved ALNs &#x2266; 5 6 (4) 1 (8) 1 (20) 9 (32)
6 &#x2266; 3 (2) 0 (0) 1 (20) 10 (36)
The maximum size of involved ALNs
&#x2266; 5 mm 10(48) 5 (83) 0 (0) 0 (0)
5 mm < metastasis < 10 mm 7(33) 1 (17) 2 (50) 6 (21)
10 mm &#x2266; 4(19) 0 (0) 2 (50) 22(79)
Nuclear grade of involved ALNs
Grade 1 and 2 16(76) 3 (50) 4 (100) 13(46)
Grade 3 5(24) 3 (50) 0 (0) 15(54)
Frequency of involved ALNs 15% 50% 80% 100%
Indications of ALND/PSC SNB FNAC/Bx is needed FNAC/Bx is needed Acceptable
Total 138 (100) 12 (100) 5 (100) 28 (100)
AUS, Axillary ultrasound; ALN, Axillary lymph node; ALND, ALN dissection; PSC, Primary systemic chemotherapy; No., Number; pts, patients; 
FNAC, Fine needle aspirationBMC Cancer 2008, 8:165 http://www.biomedcentral.com/1471-2407/8/165
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ance of axillary ultrasonography, the present results
showed higher outcome than others' previous studies [15-
17]. In our previous study, AUS was performed using an
SSD-650CL (Aloka, Tokyo, Japan), an old model of SSD-
6500, and indicated sensitivity, specificity, PPV, and over-
all accuracy of 45, 97, 92.6, and 75%, respectively [5]. Fur-
thermore an ultrasound specialist performed axillary
investigation in the present study. From these reasons, we
considered the present results were superior to those in
our previous study.
Differences in criteria for judgment of axillary status or in
the type of ultrasound device might have given rise to such
inconsistency. Furthermore, although ultrasonography is
less-invasive and relatively easy to apply, experienced
skills are required to judge AUS-positive nodes. We some-
times wavered in our judgement whether ALNs were pos-
itive or not when ultrasound image of lymph nodes was
less than 10 mm in diameter but homogeneously hypoe-
choic in centric area. From these reasons, AUS alone
might be difficult to determine axillary staging.
We classified patients into 4 categories of axillary status
according to 18F-FDG PET/CT and ultrasonography (Table
5).
Category 1 showed the patients who have AUS-negative
lymph nodes without axillary 18F-FDG uptake. Fifteen
percent of these 138 patients had ALNs involvement.
Characteristics of ALN involvement were lesser number,
smaller sizes, and lower nuclear grade of metastatic foci
(Table 5). For these patients, SNB was successfully per-
formed as shown in Table 3, and SNB is recommended to
assess axillary nodal status.
Category 2 and 3 showed the patients having discrepancy
between the axillary examinations of AUS and 18F-FDG
uptake.
Category 2 showed the patients having 18F-FDG uptake
but negative AUS. Half of these patients have metastatic
foci in their axilla. The reason of the discrepancy was
related to the fact that metastatic foci of small size (5 mm
or less) and/or higher nuclear grade was detected by 18F-
FDG uptake but were not by AUS.
Category 3 showed the patients having positive AUS with-
out axillary 18F-FDG uptake. We found 4 (80%) of 5
patients had ALN involvement. The characteristic of these
metastastic foci was lower nuclear grade. This result are in
keeping with previous reports [8-10].
The conclusions could not be determined because the
number of patients in categories 2 and 3 have been lim-
ited, but we could indicate lymph nodes having discrep-
ancy in diagnosis between AUS and axillary 18F-FDG
uptake were found to be frequently metastasized. When
the discrepancy occurred between these two modalities,
therefore, we suggest further axillary investigations such as
core-needle biopsy, or fine needle aspiration cytology to
evaluate precisely axillary nodal status.
We confirmed the positive lymph nodes found by 18F-
FDG-PET matched the SNB results in all patients of cate-
gory 2 that had involved SNs and received subsequent
axillary dissection (shown in Table 6).
Category 4 showed the patients had double-positive ALNs
of AUS and 18F-FDG uptake. PPV for detecting ALN
involvement was 100%. These patients were recom-
mended to undergo ALND without SLN. In addition, it
might be rational to consider that patients having AUS
positive nodes and axillary 18F-FDG uptake will have PSC
without biopsy or fine needle aspiration cytology to the
axilla.
Table 6: Diagnostic performance of SNB for axillary staging in 18 F-FDG-positive and AUS-negative patients of category 2
Patients SUV Involved SNs/resected SNs Involved non-SNs/resected non-SNs Ax dissection
1 8.1 1/1 0/10 Performed
2 2.5 1/1 0/17 Performed
3 2.4 1/2 0/12 Performed
4 1.4 1/3 0/21 performed
5 1.3 4/4 0/12 performed
6 0.7 1/4 0/6 performed
7 1.5 0/1 - not performed
8 1 0/4 - not performed
9 1 0/1 0/1 not performed
10 1 0/4 0/1 not performed
11 0.9 0/1 0/2 not performed
12 0.9 0/4 0/1 not performed
AUS, Axillary ultrasound;SUV, Standardized uptake value; SNs, Sentinel nodes, Ax, AxillaryBMC Cancer 2008, 8:165 http://www.biomedcentral.com/1471-2407/8/165
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Semiquantitative assessment of 18F-FDG PET/CT for the 
axilla
Table 4 showed higher SUV were significantly correlated
with nuclear grade 3 and maximum size of metastatic foci
but not with number of involved ALNs. These results also
appear to reveal biological significance of axillary 18F-FDG
accumulated to metastasized cancer cells.
When the cut-off of SUV exceeded 1.8, specificity and PPV
of  18F-FDG PET/CT were almost 100%, but sensitivity
notably decreased to 36% or lower.
From the present results, appropriate determination of the
cut-off of SUV appeared possible to evaluate ALN involve-
ment by means of 18F-FDG uptake. Especially by setting of
cutoff of SUV, we could predict ALN involvement with
excellent specificity and PPV. The cut-off of SUV for ALN
involvement varies from 1.2 to 2.3 among reports previ-
ously published [9,11]. The inter-institutional standardi-
zation of the cut-off value-off SUV for ALN evaluation
remains to be settled.
Thus, we found that axillary 18F-FDG uptake added incre-
mental diagnostic confidence to AUS. Richard L et al
reported that 18F-FDG PET may have a role in assessing
patients with medially or superiorly situated breast can-
cers that may drain preferentially or exclusively to internal
mammary or supraclavicular nodes[10]. A. Gil-Rendo et
al also described that an advantage of 18F-FDG PET was to
be able to detect internal mammary node metastasis,
which is often clinically occult and poorly visualized by
conventional modality including ultrasonography [8].
We experienced a patient having 18F-FDG uptake in a par-
asternal lymph node in spite of double-negativity in AUS
and axillary 18F-FDG uptake. The lymph node has been
proven to be metastasized by fine-needle aspiration cytol-
ogy. Another patient who have double-positivity in AUS
and axillary 18F-FDG uptake, also showed 18F-FDG uptake
in infraclavicular lymph nodes. These two patients had
chosen PSC, having been ineligible for this study proto-
col.
Thus, we considered the whole-body 18F-FDG PET/CT
would be informative for imaging investigations for
regional nodes involvement as well as distant metastasis
[12,18].
Conclusion
In conclusion, the diagnostic accuracy of visual assess-
ment of 18F-FDG PET/CT was almost equivalent to that of
AUS in sensitivity, specificity, and overall accuracy. When
cut-off of SUV was set at 1.8 or more, specificity and PPV
was each 100%. However, there are numerous factors that
will influence SUV results and we should take into consid-
eration the limited value of SUV in breast.
To our knowledge, this is the first study to compare
between 18F-FDG PET/CT and ultrasonography for detect-
ing of ALN involvement.
Considering their limited sensitivities, the high radiation
exposure by 18F-FDG PET/CT and also costs of the exami-
nation, it is likely that AUS will be more cost-effective in
detecting massive axillary tumor burden. However, when
we cannot judge the axillary staging using AUS alone, met-
abolic approach of 18F-FDG PET/CT for axillary staging
would enable us a much more confident diagnosis.
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